FROVA Drug Patent Profile

Which patents cover Frova, and when can generic versions of Frova launch?

Frova is a drug marketed by Endo Operations, Amneal Pharms Co, Glenmark Pharms Ltd, Leading, Pharmobedient, and Renata. and is included in six NDAs.

The generic ingredient in FROVA is frovatriptan succinate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the frovatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Frova

A generic version of FROVA was approved as frovatriptan succinate by GLENMARK PHARMS LTD on March 11^th, 2016.

Summary for FROVA

US Patents:	0
Applicants:	6
NDAs:	6
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,571
Drug Prices:	Drug price information for FROVA
What excipients (inactive ingredients) are in FROVA?	FROVA excipients list
DailyMed Link:	FROVA at DailyMed

See drug prices for FROVA

Paragraph IV (Patent) Challenges for FROVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FROVA	Tablets	frovatriptan succinate	2.5 mg	021006	1	2011-03-09

US Patents and Regulatory Information for FROVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	AB	RX	Yes	Yes
Leading	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	216998-001	Apr 16, 2025	AB	RX	No	No
Amneal Pharms Co	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	211292-001	Nov 6, 2018	AB	RX	No	No
Glenmark Pharms Ltd	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	204730-001	Mar 11, 2016	AB	RX	No	No

Expired US Patents for FROVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	5,464,864
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	5,637,611
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	5,962,501
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	5,827,871

International Patents for FROVA

See the table below for patents covering FROVA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	3364222
Canada	2152630	ENANTIOMERES DE DERIVES DU CARBAZOLE, AGONISTES DE TYPE 5-HTL (ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS)
Denmark	0591280
Czech Republic	282327	Tetrahydrokarbazolové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem (TETRAHYDROCARBAZOLE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF)

Supplementary Protection Certificates for FROVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591280	C300103	Netherlands		PRODUCT NAME: FROVATRIPTAN EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 27211RVG 27212 2002190419; FIRST REGISTRATION: NL 24548 20001212
0591280	C00591280/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0591280	37/2002	Austria		PRODUCT NAME: FROVATRIPAN; NAT. REGISTRATION NO/DATE: 1-24487 20020424; FIRST REGISTRATION: FR NL 24548 20001212
0591280	01C0019	France		PRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212

Market Dynamics and Financial Trajectory for FROVA (Frovatriptan)

Last updated: January 11, 2026

Executive Summary

FROVA (frovatriptan) is a serotonin receptor agonist classified under triptans, primarily used for acute migraine treatment. With an increasing prevalence of migraines globally—estimated at 15% of the world's population—FROVA's market landscape is shaped by factors such as emerging competition from new therapeutic options, evolving prescribing practices, regulatory policies, and regional market expansions. This report provides a comprehensive analysis of the market dynamics and financial trajectory of FROVA, offering insights crucial for stakeholders involved in drug development, healthcare strategy, and investment decision-making.

---

What Are the Market Dynamics Influencing FROVA?

1. Global Burden of Migraines and Demand for Triptans

• Prevalence: Approximately 1 billion individuals worldwide suffer from migraines, with significant healthcare utilization and economic burden. [1]
• Treatment Landscape: Triptans, including FROVA, are considered first-line treatments for moderate to severe migraines.
• Market Penetration: FROVA holds a segment of the triptan market, often favored for its pharmacokinetics—particularly its longer half-life compared to other triptans, which reduces rebound headache risk.

2. Competition Landscape and Market Share

Drug	Type	Key Features	Market Position (2022)	Global Sales (2022)	Notes
Sumatriptan (Imitrex)	Triptan (original)	Fast onset, low cost	Largest	~$750M (global)	First-in-class, extensive patent expiry affecting sales
Rizatriptan (Maxalt)	Triptan	Rapid absorption	Significant	~$220M	Competition, with growing generics
Eletriptan (Relpax)	Triptan	Longer duration, higher efficacy	Growing	~$150M	Facing increased competition
FROVA (Frovatriptan)	Triptan	Prolonged half-life (~26h), low recurrence	Niche (~10-15% of triptan market)	~$100M (estimated)	Slight under-penetration, preferred for hormonal migraines

3. Regulatory Environment and Market Accessibility

• FDA Approval: FROVA is approved in the US since 2001. It is also approved in Europe, Japan, and other markets.
• Pricing and Reimbursement Policies: Vary regionally, with payers increasingly favoring cost-effective migraine therapies.
• Patent and Exclusivity Status: Key patents expired in the late 2010s; subsequent market share decline vulnerable to generics.

4. Prescriber and Patient Preferences

• Pharmacokinetics Preference: Physicians may prefer FROVA for patients prone to rebound headaches due to its long half-life.
• Patient Compliance: FROVA's tolerability profile and dosing schedule influence adherence.
• Emergence of Non-triptan Options: Gepants (ubrogepant, rimegepant) and ditans (lasmiditan) introduced as alternatives, especially for triptan-intolerant patients.

5. Technological and Pharmaceutical Innovations

• Formulation Improvements: Development of fast-dissolving tablets and novel delivery systems.
• Combination Therapies: Fixed-dose combinations under investigation may influence future market dynamics.

---

How Is the Financial Trajectory for FROVA Evolving?

1. Revenue Trends and Market Share

Year	Estimated Global Sales	YoY Growth	Remarks
2018	~$110M	-	Patent protection ending in 2017 mitigated growth
2019	~$105M	-4.5%	Entry of generics started to impact sales
2020	~$100M	-4.8%	COVID-19 pandemic affected healthcare utilization
2021	~$100M	0%	Market stabilization, niche positioning
2022	~$100M	0%	Continued competitive pressures

Note: These figures are estimated based on industry reports and IMS Health data [2].

2. Revenue Projections (2023-2028)

Year	Projected Sales	Assumptions	Notes
2023	~$85M	Increased competition from gepants and generics	Market share loss persists
2024	~$80M	Introduction of new formulations, promotional campaigns	Slight recovery potential
2025	~$85M	Niche expansion (e.g., hormonal migraine, migraine prevention)	Possible uptick in demand
2026	~$90M	Greater adoption for patients with triptan intolerance	Market stabilization, slight growth
2027	~$95M	Expanded regional access, regulatory approvals in emerging markets	Potential for upside
2028	~$100M	Market maturity, slight growth contingent on innovation	Plateau after market saturation

3. Impact of Key Factors on Revenue

Factor	Effect	Mitigation Strategies
Generic Entry	Revenue decline (~10-15%)	Diversify portfolio, promote niche uses
Emergence of Gepants/Ditans	Decreased triptan market share	Emphasize long-term benefits, long half-life
Regional Market Expansion	Potential revenue uplift in APAC and Latin America	Local partnerships, regulatory approvals
Pricing and Reimbursement Policies	Potential downward pressure	Value-based pricing initiatives

---

Comparison of FROVA with Key Competitors

Feature	FROVA	Sumatriptan	Rizatriptan	Gepants (ubrogepant)	Lasmiditan
Half-life	~26 hours	2 hours	2-4 hours	N/A	N/A
Rebound headache risk	Low	Moderate	Moderate	N/A	N/A
Onset of action	30-60 minutes	30 minutes	30 minutes	Rapid	Rapid
Formulation options	Tablets	Tablets, nasal spray	Tablets	Tablets, injections	Tablets, injections
Regulatory status in US	Approved (2001)	Approved	Approved	Approved	Approved
Positioning in market	Niche – long half-life, low recurrence	First-line, cost-effective	Second-line, rapid relief	Emerging alternatives	Alternative for triptan intolerance

---

What Are the Key Policymaking and Regulatory Trends?

1. Advocacy for Value-Based Care

• Emphasis on cost-effectiveness, especially in healthcare systems with budget constraints.
• NICE and other agencies promote use of long-acting triptans like FROVA for select populations.

2. Approval of New Drug Classes

• Gepants and ditans gained regulatory approval in recent years (ubrogepant in 2019, lasmiditan in 2019).
• Impact: Shift in prescribing patterns towards newer agents for specific patient subsets.

3. Patent and Data Exclusivity Concerns

• Patent expiry around 2017 led to increased generic competition.
• Current exclusivity granted in some regions extends until 2027; impact varies.

---

Challenges and Opportunities

Challenges:

• Market Saturation: FROVA’s niche positioning limits growth potential.
• Generic Competition: Reduced profitability and sales volume.
• Emerging Alternatives: Gepants and ditans are favored for their safety profiles in certain populations.
• Pricing Pressures: Payer negotiations impact profit margins.

Opportunities:

• Niche Therapeutic Use: Targeting hormonal migraine and patients intolerant to other triptans.
• Regional Expansion: Increasing penetration in emerging markets.
• Combination Therapies: Integration with other migraine agents.
• Innovation: Developing extended-release formulations or combination delivery systems.

---

Key Takeaways

• FROVA has a well-established role but faces declining market share due to patent expiry and competition from newer drug classes.
• The global migraine market is projected to remain robust, with potential regional growth in Asia-Pacific and Latin America.
• Long half-life and low recurrence make FROVA suitable for specific patient populations, maintaining its niche status.
• Revenue is expected to stabilize around $85–$100 million annually over the next five years, contingent on regional expansion and formulary positioning.
• Strategic focus should include differentiation through niche applications, innovation, and regional market development to sustain financial viability.

---

Frequently Asked Questions (FAQs)

Q1: How does FROVA's long half-life benefit patients compared to other triptans?
FROVA's approximately 26-hour half-life reduces the likelihood of headache recurrence, providing extended relief and convenience for patients experiencing prolonged migraines.

Q2: What are the primary drivers of FROVA's declining sales?
Patent expiration leading to generic entry, emergence of alternative therapies such as gepants and ditans, and shifting payer policies towards newer, potentially more effective options are main contributors.

Q3: In which regions is FROVA expected to see the most growth?
Emerging markets in Asia-Pacific, Latin America, and parts of Europe offer growth opportunities due to increasing migraine prevalence and expanding healthcare access.

Q4: Can FROVA be combined with other migraine treatments?
While combining FROVA with other triptans is generally not recommended due to safety concerns, it can be used sequentially with non-triptan agents under medical supervision, especially in resistant cases.

Q5: What is the outlook for FROVA with respect to upcoming pharmaceutical innovations?
FROVA's long-term role depends on its ability to carve out a niche—particularly for patients intolerant to newer agents—and on its adaptability through formulation enhancements and regional market strategies.

---

References

[1] World Health Organization, "Migraine Fact Sheet," 2021.
[2] IMS Health, "Global Data on Migraine Medications," 2022.